Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillation
M Jansson, S Själander, V Sjögren, H Renlund… - Thrombosis …, 2020 - Elsevier
Abstract Introduction Direct oral anticoagulants (DOACs) have been proven non-inferior or
superior to warfarin in preventing stroke and systemic embolism, with a lower risk of major …
superior to warfarin in preventing stroke and systemic embolism, with a lower risk of major …
Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
NW Andersson, H Svanström, M Lund… - International journal of …, 2018 - Elsevier
Background The comparative effectiveness and safety of individual direct oral
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …
Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study
OCW Rutherford, C Jonasson… - European Heart …, 2020 - academic.oup.com
Aims The aim of this study was to compare the risk of stroke or systemic embolism (SE) and
major bleeding in patients with atrial fibrillation (AF) using dabigatran, rivaroxaban, and …
major bleeding in patients with atrial fibrillation (AF) using dabigatran, rivaroxaban, and …
Differences in safety and efficacy of oral anticoagulants in patients with non‐valvular atrial fibrillation: A Bayesian analysis
Z Sun, Y Liu, Y Zhang, X Guo… - International Journal of …, 2019 - Wiley Online Library
Background Novel oral anticoagulants are the cornerstone of therapy for non‐valvular atrial
fibrillation patients to lower the risk of ischaemic stroke. Given the lack of head‐to‐head …
fibrillation patients to lower the risk of ischaemic stroke. Given the lack of head‐to‐head …
Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
LJ Kjerpeseth, R Selmer, I Ariansen, Ø Karlstad… - PLoS …, 2019 - journals.plos.org
Objective To compare effectiveness and safety of warfarin and the direct oral anticoagulants
(DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation in routine …
(DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation in routine …
Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large …
TC Villines, A Ahmad, M Petrini, W Tang… - European Heart …, 2019 - academic.oup.com
Aims We used the US Department of Defense Military Health System database to compare
the safety and effectiveness of direct oral anticoagulants (DOACs) in patients with non …
the safety and effectiveness of direct oral anticoagulants (DOACs) in patients with non …
Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: a multi‐database cohort study with meta‐analysis
M Durand, ME Schnitzer, M Pang… - British Journal of …, 2021 - Wiley Online Library
Aims There are conflicting signals in the literature about comparative safety and
effectiveness of direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF) …
effectiveness of direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF) …
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin
GYH Lip, A Keshishian, S Kamble… - Thrombosis and …, 2016 - thieme-connect.com
In addition to warfarin, there are four non-vitamin K antagonist oral anticoagulants (NOACs)
available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited …
available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited …
Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation
S Själander, V Sjögren, H Renlund, B Norrving… - Thrombosis research, 2018 - Elsevier
Introduction New oral anticoagulants are non-inferior compared with warfarin regarding
stroke prevention in atrial fibrillation, with similar or decreased risk of bleeding. However, it is …
stroke prevention in atrial fibrillation, with similar or decreased risk of bleeding. However, it is …
Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the …
GYH Lip, X Pan, S Kamble, H Kawabata… - … journal of clinical …, 2016 - Wiley Online Library
Background Limited data are available about the real‐world safety of non‐vitamin K
antagonist oral anticoagulants (NOAC s). Objectives To compare the major bleeding risk …
antagonist oral anticoagulants (NOAC s). Objectives To compare the major bleeding risk …
相关搜索
- atrial fibrillation effectiveness and safety
- dabigatran rivaroxaban apixaban for effectiveness
- treatment with apixaban direct comparisons
- treatment with apixaban effectiveness and safety
- direct comparisons effectiveness and safety
- treatment with apixaban atrial fibrillation
- atrial fibrillation direct comparisons
- safety of apixaban rivaroxaban in patients
- dabigatran rivaroxaban atrial fibrillation
- atrial fibrillation oral anticoagulants
- defense population effectiveness and safety
- atrial fibrillation bayesian analysis
- meta analysis effectiveness and safety
- safety of treatment direct comparisons
- dabigatran rivaroxaban effectiveness and safety
- atrial fibrillation apixaban for effectiveness